🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Myotonic Dystrophy Type 1

Herombopag Treated T-DM1 Induced Platelet Reduction NCT07257809Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Herombopag Olamine Tablets An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) NCT07220603Phase 23 sites📍 Calgary📍 Ottawa📍 Saguenay PepGen Inc · Tests: PGN-EDODM1 Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy NCT06075693n/a1 site📍 Boston Massachusetts General Hospital Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy NCT07630389n/a1 site📍 Rochester University of Rochester Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy NCT06693037n/a1 site📍 Beijing Shu Wang Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry NCT00082108n/a1 site📍 Rochester University of Rochester Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension NCT06747884n/a4 sites📍 Little Rock📍 Kansas City📍 Richmond Virginia Commonwealth University The United Kingdom National Registry for Myotonic Dystrophy NCT04003363n/a1 site📍 Newcastle upon Tyne Newcastle University · Tests: Patient Registry DMCRN-02-001: Assessing Pediatric Endpoints in DM1 NCT05224778n/a5 sites📍 Los Angeles📍 Fairway📍 Rochester Virginia Commonwealth University JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer NCT06846437Phase 31 site📍 Shanghai Shanghai JMT-Bio Inc. · Tests: JSKN003, Trastuzumab emtansine (T-DM1) The Spanish National Registry for Myotonic Dystrophy Type 1 NCT07385443n/a8 sites📍 Multiple Locations📍 Multiple Locations📍 Multiple Locations Fundació Institut Germans Trias i Pujol · Tests: Patient Registry Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy NCT05004129Phase 2, Phase 314 sites📍 Little Rock📍 Los Angeles📍 Palo Alto AMO Pharma Limited · Tests: Tideglusib Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) NCT03981575n/a17 sites📍 La Jolla📍 Los Angeles📍 Denver Virginia Commonwealth University A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 NCT06844214Phase 1, Phase 210 sites📍 Gainesville📍 Tampa📍 New York Sanofi · Tests: SAR446268 A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy NCT06830889Phase 32 sites📍 Nanjing📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, T-DM1 Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension NCT07700225n/a1 site📍 Richmond Virginia Commonwealth University Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas NCT04620187Phase 213 sites📍 Atlanta📍 Chicago📍 Boston Dana-Farber Cancer Institute · Tests: Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 NCT07486934Phase 343 sites📍 La Jolla📍 Los Angeles📍 Palo Alto Dyne Therapeutics · Tests: zeleciment basivarsen (DYNE-101), Placebo Study of ATX-01 in Participants With DM1 NCT06300307Phase 1, Phase 212 sites📍 Los Angeles📍 Gainesville📍 Iowa City ARTHEx Biotech S.L. · Tests: ATX-01, Placebo Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer NCT05288777Phase 2, Phase 31 site📍 Charlottesville University of Virginia · Tests: T-DM1, Capecitabine, External Beam Radiation Therapy 0, External Beam Radiation Therapy 1 Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology NCT07136844NA1 site📍 Liège Centre Hospitalier Universitaire de Liege · Tests: Syde, Dynamometric measurements of muscle strength, The 6-minute walk test (6MWT), The 10-meter test (10MWT), The 4 sta… Remote Assessments and Genetic Determinants of Myotonic Dystrophy NCT07505342n/a1 site📍 Rochester University of Rochester A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 NCT06667453Phase 212 sites📍 Calgary📍 Ottawa📍 Chicoutimi PepGen Inc · Tests: PGN-EDODM1, Placebo Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy NCT06828588EARLY Phase 11 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: [68Ga]Ga-ABY-025 Pelvic Floor Muscle Training for Women with Myotonic Dystrophy NCT06316778NA1 site📍 Jonquière Université de Sherbrooke · Tests: Pelvic floor muscle training ATEMPT 2.0: Adjuvant T-DM1 vs TH NCT04893109Phase 253 sites📍 San Francisco📍 Derby📍 Fairfield Dana-Farber Cancer Institute · Tests: trastuzumab-emtansine, Trastuzumab SC, Paclitaxel The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 NCT06523400Phase 37 sites📍 Leuven📍 Aarhus📍 München Lupin Ltd. · Tests: Mexiletine granules for prolonged-release oral suspension, Placebo A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer NCT07673029Phase 370 sites📍 Bengbu📍 Fuyang📍 Hefei GeneQuantum Healthcare (Suzhou) Co., Ltd. · Tests: GQ1005, T-DM1 A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) NCT05673928Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Trastuzumab emtansine, Tucatinib Personalized Training for People With Rare Neuromuscular Disorders NCT06708468NA5 sites📍 Bergen📍 Molde📍 Namsos Oslo University Hospital · Tests: Exercise, Usual Care
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy